Efgartigimod Provides Genuine Benefit For Myasthenia Gravis Disease Overview Efgartigimod, a neonatal Fc receptor inhibitor, has recently received approval for the treatment of myasthenia gravis (MG). This retrospective cohort study systematically evaluated the short- and long-term efficacy of efgartigimod in patients with refractory MG. Sixteen patients with autoimmune acetylcholine receptor MG, who
Tag: Efgartigimod
